1
|
Schilbach K, Alkhaled M, Welker C, Eckert F, Blank G, Ziegler H, Sterk M, Müller F, Sonntag K, Wieder T, Braumüller H, Schmitt J, Eyrich M, Schleicher S, Seitz C, Erbacher A, Pichler BJ, Müller H, Tighe R, Lim A, Gillies SD, Strittmatter W, Röcken M, Handgretinger R. Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. Oncoimmunology 2015; 4:e1014760. [PMID: 26140238 PMCID: PMC4485786 DOI: 10.1080/2162402x.2015.1014760] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Revised: 01/27/2015] [Accepted: 01/29/2015] [Indexed: 02/07/2023] Open
Abstract
Stimulating the immune system to attack cancer is a promising approach, even for the control of advanced cancers. Several cytokines that promote interferon-γ-dominated immune responses show antitumor activity, with interleukin 12 (IL-12) being of major importance. Here, we used an antibody-IL-12 fusion protein (NHS-IL12) that binds histones of necrotic cells to treat human sarcoma in humanized mice. Following sarcoma engraftment, NHS-IL12 therapy was combined with either engineered IL-7 (FcIL-7) or IL-2 (IL-2MAB602) for continuous cytokine bioavailability. NHS-IL12 strongly induced innate and adaptive antitumor immunity when combined with IL-7 or IL-2. NHS-IL12 therapy significantly improved survival of sarcoma-bearing mice and caused long-term remissions when combined with IL-2. NHS-IL12 induced pronounced cancer cell senescence, as documented by strong expression of senescence-associated p16INK4a and nuclear translocation of p-HP1γ, and permanent arrest of cancer cell proliferation. In addition, this cancer immunotherapy initiated the induction of myogenic differentiation, further promoting the hypothesis that efficient antitumor immunity includes mechanisms different from cytotoxicity for efficient cancer control in vivo.
Collapse
Key Words
- CIP1, CDK-interacting protein 1
- DNAM-1, DNAX accessory molecule-1
- KIR, killer-cell immunoglobulin-like receptor
- M1/M2 macrophages
- MICA/B, MHC class I polypeptide-related sequence A/B
- NKG, natural killer group
- NSG, NOD SCID gamma chain knock out mouse
- PCNA, proliferating cell nuclear antigen
- PVR, poliovirus receptor
- RMS, rhabdomyosarcoma, (eRMS: embryonal, aRMS: alveolar)
- ROI, region of interest
- RORC, RAR-related orphan receptor C
- SCT, stem cell transplantation
- SPECT/CT, single-photon emission computed tomography
- TH1-induced senescence
- TH17 cells
- TRBV, T-cell receptor beta chain
- ULBP, UL16 binding protein
- WAF, wild-type activating fragment
- cancer-targeted IL-12
- differentiation
- humanized mice
- immunocytokine
- immunotherapy
- pHP1γ, phosphorylated heterochromatin protein 1 gamma
- rhabdomyosarcoma
- tumor-infiltrating lymphocytes
Collapse
Affiliation(s)
- Karin Schilbach
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| | - Mohammed Alkhaled
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| | - Christian Welker
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| | - Franziska Eckert
- Department of Radiation Oncology; Eberhard Karls University ; Tübingen, Germany
| | - Gregor Blank
- Department of General, Visceral and Transplant Surgery; University Hospital ; Tübingen, Germany
| | - Hendrik Ziegler
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| | - Marco Sterk
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| | - Friederike Müller
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| | - Katja Sonntag
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| | - Thomas Wieder
- Department of Dermatology; Eberhard Karls University ; Tübingen, Germany
| | - Heidi Braumüller
- Department of Dermatology; Eberhard Karls University ; Tübingen, Germany
| | - Julia Schmitt
- Werner Siemens Imaging Center; Department for Preclinical Imaging and Radiopharmacy; Eberhard Karls University ; Tübingen, Germany
| | - Matthias Eyrich
- University of Würzburg; Department of Pediatrics; Interdisciplinary Stem Cell Laboratory ; Würzburg, Germany
| | - Sabine Schleicher
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| | - Christian Seitz
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| | - Annika Erbacher
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| | - Bernd J Pichler
- Werner Siemens Imaging Center; Department for Preclinical Imaging and Radiopharmacy; Eberhard Karls University ; Tübingen, Germany
| | - Hartmut Müller
- Department of General Pathology; Institute of Pathology; Eberhard Karls University ; Tübingen, Germany
| | - Robert Tighe
- EMD Serono Research Institute ; Billerica, MA USA
| | - Annick Lim
- Départment d'Immunologie; Institute Pasteur ; Paris, France
| | | | | | - Martin Röcken
- Department of Dermatology; Eberhard Karls University ; Tübingen, Germany
| | - Rupert Handgretinger
- Department of General Pediatrics; Oncology/Hematology; University Children's Hospital ; Tübingen, Germany
| |
Collapse
|